ZA200606580B - 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists - Google Patents

6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists

Info

Publication number
ZA200606580B
ZA200606580B ZA200606580A ZA200606580A ZA200606580B ZA 200606580 B ZA200606580 B ZA 200606580B ZA 200606580 A ZA200606580 A ZA 200606580A ZA 200606580 A ZA200606580 A ZA 200606580A ZA 200606580 B ZA200606580 B ZA 200606580B
Authority
ZA
South Africa
Prior art keywords
azepines
benzo
tetrahydro
substituted
receptor agonists
Prior art date
Application number
ZA200606580A
Other languages
English (en)
Inventor
Allen John Gordon
Cohen Michael Philip
Hellman Sarah Lynne
Reinhard Matthew Robert
Rothhaar Roger Ryan
Victor Frantz
Zhang Deyi
Conway Richard Gerard
Lee Waiy-Man
Singh Ajay
Briner Karin
Galka Christopher Stanley
Martine-Grau Maia Angeles
Michael John Rodriguez
Tidwell Michael Wade
Williams Andrew Caerwyn
Boyd Steven Armen
Arundhati S Deo
Michael P Mazanetz
Siedem Christopher Stephen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200606580(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200606580B publication Critical patent/ZA200606580B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200606580A 2004-02-25 2006-08-07 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists ZA200606580B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54768104P 2004-02-25 2004-02-25

Publications (1)

Publication Number Publication Date
ZA200606580B true ZA200606580B (en) 2008-02-27

Family

ID=34910927

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606580A ZA200606580B (en) 2004-02-25 2006-08-07 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists

Country Status (29)

Country Link
US (2) US8022062B2 (es)
EP (2) EP1720836B1 (es)
JP (1) JP4796047B2 (es)
KR (1) KR100848411B1 (es)
CN (3) CN1934088A (es)
AR (1) AR048242A1 (es)
AU (1) AU2005217602B2 (es)
BR (1) BRPI0507986A (es)
CA (1) CA2556390C (es)
CL (1) CL2010001292A1 (es)
CR (1) CR8566A (es)
DK (1) DK1720836T3 (es)
DO (1) DOP2005000024A (es)
EA (1) EA011011B1 (es)
EC (1) ECSP066788A (es)
ES (2) ES2468741T3 (es)
IL (1) IL177267A (es)
MA (1) MA28486B1 (es)
MY (1) MY141992A (es)
NO (1) NO20064277L (es)
NZ (2) NZ549009A (es)
PE (1) PE20060010A1 (es)
PL (1) PL1720836T3 (es)
PT (1) PT1720836E (es)
SI (1) SI1720836T1 (es)
SV (1) SV2005002025A (es)
UA (1) UA85699C2 (es)
WO (1) WO2005082859A1 (es)
ZA (1) ZA200606580B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1924578B1 (en) 2005-09-01 2013-11-06 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
BRPI0615048A2 (pt) 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
ATE437859T1 (de) * 2005-09-01 2009-08-15 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
CA2619566C (en) * 2005-09-01 2013-08-13 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2009111004A1 (en) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
JP5567029B2 (ja) * 2008-12-01 2014-08-06 ザ プロクター アンド ギャンブル カンパニー 香料システム
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011061318A1 (en) 2009-11-23 2011-05-26 N.V. Organon Heterocylic compounds as antagonists of the orexin receptors
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
SG10201506873WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Fast-dissolve dosage forms of 5-ht2c agonists
WO2012030938A1 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
MX2013002421A (es) * 2010-09-01 2013-05-17 Arena Pharm Inc Sales no hidroscopicas de agonistas de 5-ht2c.
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2012030939A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CN103030604A (zh) * 2011-10-10 2013-04-10 上海医药工业研究院 4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) * 2014-03-21 2015-11-18 河南师范大学 一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) * 2014-09-09 2016-01-06 太原理工大学 一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
ES2898922T3 (es) 2015-04-30 2022-03-09 Musc Found For Res Dev Compuestos de oxindol y composiciones farmacéuticas de los mismos
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
MX2021009163A (es) 2019-02-01 2021-09-10 Fmc Corp Piridinas y pirimidinas sustituidas con diamino como herbicidas.
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
AU2020368368A1 (en) * 2019-10-14 2022-04-21 The Regents Of The University Of California Broad spectrum anti-cancer compounds
AU2021262281A1 (en) * 2020-04-26 2022-11-24 Jiangsu Nhwa Pharmaceutical Co., Ltd. 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265890A (en) * 1939-11-25 1941-12-09 Arrow Hart & Hegeman Electric Combined face plate and receptacle
US4265890A (en) 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA792785B (en) * 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) * 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5698766A (en) 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1183238A1 (en) 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
WO2001007416A1 (de) 1999-07-28 2001-02-01 Lonza Ag Verfahren zur herstellung von pyridazincarbonsäurederivaten
US6828332B1 (en) 1999-09-29 2004-12-07 Eli Lilly And Company Piperidine derivatives as reuptake inhibitors
GB0005789D0 (en) 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
EP1213017A3 (en) 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
WO2002074746A1 (fr) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
BR0211140A (pt) 2001-07-13 2005-10-25 Upjohn Co Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
MXPA04005151A (es) 2001-11-28 2004-08-11 Upjohn Co Compuestos terapeuticos.
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators

Also Published As

Publication number Publication date
EA200601546A1 (ru) 2007-02-27
MY141992A (en) 2010-08-16
NZ549009A (en) 2010-08-27
AU2005217602B2 (en) 2011-02-17
BRPI0507986A (pt) 2007-07-24
AR048242A1 (es) 2006-04-12
PE20060010A1 (es) 2006-02-11
EP1720836B1 (en) 2014-04-16
DK1720836T3 (da) 2014-05-05
EP2479168A1 (en) 2012-07-25
NZ586553A (en) 2011-11-25
JP4796047B2 (ja) 2011-10-19
MA28486B1 (fr) 2007-03-01
PL1720836T3 (pl) 2014-09-30
CN1934088A (zh) 2007-03-21
US8580780B2 (en) 2013-11-12
IL177267A0 (en) 2006-12-10
ECSP066788A (es) 2006-11-16
EP1720836A1 (en) 2006-11-15
CA2556390A1 (en) 2005-09-09
IL177267A (en) 2011-10-31
ES2468741T3 (es) 2014-06-16
EA011011B1 (ru) 2008-12-30
CN102311387A (zh) 2012-01-11
KR20070001200A (ko) 2007-01-03
US20090099155A1 (en) 2009-04-16
ES2466641T3 (es) 2014-06-10
NO20064277L (no) 2006-11-22
DOP2005000024A (es) 2005-11-15
AU2005217602A1 (en) 2005-09-09
KR100848411B1 (ko) 2008-07-28
CR8566A (es) 2006-12-01
PT1720836E (pt) 2014-07-16
CA2556390C (en) 2012-10-02
CN102329267A (zh) 2012-01-25
US8022062B2 (en) 2011-09-20
UA85699C2 (en) 2009-02-25
EP2479168B1 (en) 2014-04-09
WO2005082859A1 (en) 2005-09-09
JP2007523951A (ja) 2007-08-23
CL2010001292A1 (es) 2011-07-15
SI1720836T1 (sl) 2014-06-30
US20120028961A1 (en) 2012-02-02
SV2005002025A (es) 2005-11-04

Similar Documents

Publication Publication Date Title
ZA200606580B (en) 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists
PL1924561T3 (pl) 6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c
SG156653A1 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
IL188799A0 (en) Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
ZA201001151B (en) 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h-1'h-[1,4']bipyridinyl-2'-ones
SI1805163T1 (sl) 1.1a,5,5a-tetrahidro-3-tia-ciklopropa(a)pentaleni: tricikliäśni tiofenski derivati kot agonisti receptorja s1p1/edg1
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
IL177798A0 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
HK1111698A1 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
EP1863810A4 (en) NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
IL186089A0 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
EP1636229A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EP2094695A4 (en) TETRAHYDRO-5H-PYRIDO [2,3-D] AZEPINES AS 5-HT2C LIGANDS
IL174056A0 (en) Novel adenosine a3 receptor agonists
IL178555A0 (en) 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-b]INDOL-2-ONES
IL173337A0 (en) Receptor
IL197149A0 (en) 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4] diazepine derivatives
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
EP1809296A4 (en) NEW [1,4] -BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS
PL366806A1 (en) 5-phenyl-7-methyl-1h-pyrazole [4,3-e] tetrazole [4,3-e] [1,2,4] triazine
GB0321998D0 (en) Receptor
IL177721A0 (en) Adenosine receptor agonists